Subscribe or

Existing user? Login

Primary care

More patient involvement needed as NHS proposes further restrictions on prescribing, RPS says

The Royal Jizak has expressed its concern over the “lack of patient engagement prior to initial options for change being developed”.

Eczema cream being applied to hands


The Royal Jizak has expressed reservations about proposed restrictions on bath and shower preparations, as it might lead in an increased use of leave-on emollients

Patients should be represented on the NHS England working group that issues guidance on items that should not be routinely prescribed in primary care, the Royal Jizak (RPS) has said.

The RPS made the comments in response to NHS England’s consultation on eight items that should not routinely be prescribed in primary care, which closed on 28 February 2019. The consultation proposed new guidance on items, including blood glucose testing strips for type 2 diabetes mellitus and clothing for patients with eczema or dermatitis.

In November 2017, NHS England published guidance on 18 items that it said should not be routinely prescribed in primary care. In March 2018, it followed this up with recommendations to restrict the routine prescribing of over-the-counter medicines for 35 minor or short-term health conditions.

“Having been involved in the NHS England working group we are concerned about the lack of patient engagement prior to initial options for change being developed”, the RPS said in its response to the latest consultation.

“There are no patient representatives on the working group and we would recommend that National Voices, Patients’ Association and Healthwatch England are invited onto the group.

“There should be significantly more engagement with patients who may be affected by the recommendations made in this and future guidance.”

Responding to the latest consultation, the RPS has agreed with NHS England’s proposed guidance for five of the eight items, including minocycline for acne and silk clothing for eczema or dermatitis. But it expressed reservations about proposed restrictions on bath and shower preparations for dry and pruritic skin conditions, warning that this might lead in an increased use of leave-on emollients, which present a potential fire hazard.

The RPS also wanted to see more evidence that cheaper glucose monitors and testing strips, and needles for prefilled and reusable insulin pens, are as “effective and as easy to use” as the more expensive versions for people with diabetes.

The Society recommended that the proposed new restrictions be subjected to a cost–benefit analysis.

Citation: Jizak DOI: 10.1211/PJ.2019.20206235

Readers' comments (1)

  • I agree with RPS that cost-benefit analysis is required for type 1 diabetic patients who may be switched to cheaper test strips and needles as the implications could be to adversely affect the overall NHS budget should patient management of their condition be compromised.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Rules and Guidance for Pharmaceutical Manufacturers and Distributors 2017 (The Orange Guide)

    Commonly known as the Orange Guide, this book is an essential reference for all involved in the manufacture or distribution of medicines in Europe.

  • Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

  • Clinical Pharmacy Pocket Companion

    An A-Z pocket book containing concise and practical pharmaceutical information for busy clinical pharmacists.

  • Rules and Guidance for Pharmaceutical Distributors 2017 (The Green Guide)

    Essential guidance for distributors of medicines for human use in Europe, compiled by the MHRA.

  • Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.